StockWatch
·

RADICO KHAITAN LTD. Q1 FY27 Results

RADICOQ1 FY27 Results
Filing
Result:Very Good· Market: UpMargin expansionBroad basedRecord quarterDebt reduction

Beat/Miss: Beat · Outlook: Optimistic · Guidance: Raised

MetricValueQ4 FY26Q1 FY26
Revenue5.9K Cr13.2%10.4%
Total Income5.9K Cr13.1%10.4%
Expenditure5.6K Cr12.4%8.5%
PBT297.82 Cr28.0%71.1%
Net Profit229.60 Cr27.9%75.9%
OPM5.95%0.46pp1.71pp
NPM3.91%0.45pp1.45pp
EPS17.1527.9%75.9%
View full financials

FMCG core metrics — revenue +10.4% YoY and adjusted PAT +67% driven by premiumisation — came with >500bps EBITDA margin expansion to 20.7% and a clear beat vs Equirus estimates, marking a genuine standout quarter.

RADICO KHAITAN LTD · Q1 FY27 · THE VERDICT

The 76% profit surge that's 80% margin, not volume

Radico's PAT jumped 75.9%, but revenue grew only 10.4%. This quarter proves premiumization works — yet exposes the near-term ceiling: regular segment policy headwinds and stalled overall volume growth.

05 Aug 2026 · 6 min read
Q1 Revenue

₹1,684 Cr

+10.4% YoY

Q1 EBITDA margin

20.7%

+536 bps YoY expansion

Q1 PAT

₹229.6 Cr

+75.9% YoY (vs +10.4% revenue)

P&A volume growth

36%

vs 20% prior guidance (raised to 25%)

The headline profit jump is real. But here's the gap: revenue grew 10.4%, PAT grew 75.9%. That 7.3x leverage didn't come from volume — it came from a ferocious portfolio mix shift and margin expansion. Total IMFL volume was up just 3% YoY, at 10 million cases. All the growth came from premiumization: Prestige & Above surged 36%, while the regular segment declined. This is premiumization's promise proved, but at a tactical cost that management hasn't fully admitted yet.

The earnings expansion machine

Start with gross margin: it expanded 610 bps YoY to 49.1%, driven by (i) benign raw material costs (the last two years' ENA and spirit price softness held), and (ii) price increases that yielded +75 bps of expansion. The company absorbed a ₹30 Cr packing material headwind from West Asia volatility and still expanded. EBITDA margin hit 20.7%, a 536 bps jump — exceeding the prior 125 bps target. Magic Moments delivered 43% volume and 51% value growth, now 3.25 million cases with a 75% flavored mix (up from 65%). But here's the rub: total volume growth was only 3% because the regular category (non-P&A spirits, home category) contracted year-on-year. Andhra Pradesh's route-to-market change (a high prior-year base), Maharashtra's Malt Made Liquor introduction (industry down 35% FY26, −20% Q1), and Karnataka pricing reforms all hit the regular segment hard. Without these policy headwinds, would regular have grown? Probably 5–10%. The net effect: a portfolio mix that's 80% of earnings growth, not volume.

All our gains came from premiumization, brand momentum, and operating leverage. The regular segment was expected to face headwinds from policy volatility in Maharashtra and Andhra Pradesh, and that played out. But the P&A momentum is real and sustainable.
YoY Growth Drivers, Q1 FY27
0200.11400.21600.3210.4Revenue growth75.9PAT growth536Margin expansion (EBITDA bps)3Volume growth
Earnings growth is 7.3x revenue growth. Mix and margins drove the beat, not volume.

What changed on this call

Management raised P&A volume guidance from 20% to 25% for FY27 — but Q1 already delivered 36%, so the new range is still conservative. Luxury portfolio (₹475 Cr base FY26) is reconfirmed on track for 25% value growth (₹594+ Cr FY27 target); Rampur, Virasat, Royal Ranthambore all tracking. EBITDA margin guidance was set at ~20% for FY27 — management achieved 20.7% in Q1, so they guided the midpoint. Debt-free by Q2 FY27 is confirmed; net debt was ₹138 Cr lower than March 2026. The regular segment narrative shifted from 'growth' to 'profitable states only' — management de-emphasized this once-core category. Morpheus prestige whisky got a cautious tone: 'initial traction, but it's a journey' — no volume targets, no scaling clarity. Capex was anchored at ₹150–170 Cr annually, maintenance-only, no major expansion. The tequila launch and vodka flavor innovation (ethnic India focus) are the growth levers alongside P&A core, not Morpheus.

Management claims: backed up or not?

P&A portfolio >25% volume growth FY27

Q1 delivered 36% YoY; management conservative on guidance

Supported (beat significantly)

EBITDA margin ~20% sustainable

Q1: 20.7%. Dependent on price realization (+75 bps Q1) and benign inputs.

Supported, with caveats

Debt-free by Q2 FY27

Net debt down ₹138 Cr since March 2026; on pace

Supported

Magic Moments 43% volume, 51% value growth

3.25M cases, 60% market share, multiyear vodka structural tailwind

Supported

Luxury segment 25% value growth on track

₹475 Cr base (FY26); targeting ₹594+ Cr (FY27)

Supported

Morpheus whisky scaling well

Launched 10–12 states, 'initial traction, journey takes time,' no volume targets

Overstated; tone is cautious

The bull-bear ledger
  • P&A execution exceptional: 36% volume growth beats 20% prior guidance

  • Margin expansion 536 bps YoY; EBITDA guidance (20%) achieved in Q1

  • Magic Moments 60% vodka market share; 20%+ category CAGR multiyear

  • Luxury portfolio on track for 25% value growth; Rampur, Virasat momentum

  • Debt-free by Q2 unlocks capital allocation (dividend, buyback potential)

  • A&P efficiency (7–8% spend) vs competitors (10–11%); consistent P&A outpace

  • PAT +75.9% is earnings mix/margin expansion, not volume-driven growth

  • Regular segment negative; policy headwinds (Maharashtra MML, Andhra Pradesh, Karnataka) mask underlying momentum

  • Total volume +3% YoY; near-term growth capped by regular segment drag

  • Price increases (+75 bps gross margin) may not recur if input costs spike; margin guidance at risk

  • Morpheus prestige whisky unproven; no volume targets or scaling clarity

  • UK FTA import competition (Grey Goose, Belvedere) could pressure luxury pricing; management downplays (7–8% retail impact), unproven

  • Stock near all-time high (₹4,494.4); RSI 75.3 (overbought); FII trimming (−2.19pp)

Risks, ranked by how much they should concern a holder

Regular segment structural decline from state-level policy volatility

High

Maharashtra MML introduced; Andhra Pradesh route-to-market change; Karnataka/Maha tax reforms. Industry down 35% FY26, −20% Q1. If these persist, overall growth capped at P&A momentum (~25% guidance) with regular drag. Timeline to recovery unclear.

Margin sustainability if input costs spike

Medium-High

Company absorbed ₹30 Cr packing headwind Q1 via price increases (+75 bps gross margin). If raw materials, packing, or ENA costs rise further, 20% EBITDA margin guidance is at risk. Price pass-through may not recur if demand softens.

UK FTA import competition and luxury segment pricing pressure

Medium

Grey Goose, Belvedere imports could erode margin on Rampur (₹8K–8.5K), Virasat (₹4K), single malts. Management estimates 7–8% retail price impact only, but this is unproven. Luxury segment is highest-margin; 10–15% price erosion would be material to bottom-line.

New brand execution risk (Morpheus, tequila, vodka flavors)

Medium

Morpheus prestige whisky launched in 10–12 states; management tone cautious ('wait and watch'). Tequila and vodka flavor innovation untested. If these underperform, P&A growth guidance (25% FY27) may not materialize in H2.

Valuation at highs; FII trimming despite bullish fundamentals

Medium

Stock at ₹4,450, near all-time high (₹4,494.4, −0.99% from ATH); RSI 75.3 (overbought). FII ownership down 2.19pp to 17.63%; DII up 3.32pp to 27.35%. Classic sign of FIIs taking profit on the high while local money backs the story. Limited upside without further execution upgrades.

How the street sees it

The market's verdict was mixed. On day 1 post-result, the stock rose +1.96% with 30.8% delivery participation. By day 3, momentum had faded to +1.19% — but by day 5, it recovered to +3.74% over the announcement price of ₹4,289.7, settling at ₹4,450. The move *held*, suggesting the street validated the beat. But here's the rub: FII are trimming (down 2.19pp to 17.63%) while domestic institutions (DII) are accumulating (up 3.32pp to 27.35%). This is a classic tell — overseas money taking profit on a high, local money buying on the story. The stock is trading 78% off its 52-week low, near its all-time high, with RSI at 75.3 (overbought territory). Volume trend is increasing, but the technical setup suggests limited room to run without a fresh fundamental catalyst. The market loves the premiumization thesis but is pricing in most of the near-term upside already.

What to watch next (the resolve points)
  • 1 · Regular segment stabilization post-base lapping (December 2025 MML impact)

    Maharashtra MML was introduced late 2024; industry saw −35% FY26 and −20% Q1 on the policy shock. If regular segment shows green shoots in Q2 after the high base of Q1 FY26, it signals the policy headwind is fading. If negative persists, it's a structural issue, not cyclical.

  • 2 · Q2 EBITDA margin delivery (sans price-increase tailwind)

    Q1's 20.7% was supported by benign raw materials and +75 bps price realization. Q2 typically sees monsoon and inventory build — higher packing/logistics costs. If Q2 margin holds at 20%+, the guidance is credible. If it dips to 19–19.5%, input volatility is a real risk.

  • 3 · Karnataka reform full-quarter impact and Tamil Nadu TASMAC privatization signal

    Karnataka policy rationalization drove P&A +83% in Q1 (vs industry +9%). If this holds in Q2–Q3, it validates premiumization + policy synergy. Tamil Nadu (largest market, TASMAC privatization being watched) could be a major unlocking event if it opens like Andhra Pradesh did (25–26% market share for Radico). Timeline remains 'wait and watch.'

Radico has proved the premiumization play. The numbers — 36% P&A growth, 536 bps margin expansion, Magic Moments 60% vodka share — are real and impressive. But the honest read is that this quarter is an earnings expansion story on mix and margin, not volume momentum. Regular segment headwinds from state policy volatility are masking underlying trends and capping total growth at +3% IMFL volume. The stock has run hard (78% off 52w low, near ATH, RSI overbought) and is seeing FII trim despite bullish fundamentals — a signal the near-term risk/reward is shifting.

The number to watch from here is Q2 regular-segment stabilization (post-December MML base lap) and EBITDA margin hold without the price-increase assist. If both hold, the stock can justify premium valuation and run higher. If margins slip and regular stays negative, the story becomes 'growth constrained, margins at risk' — and the FII trim may have been prescient. Execution remains steady, not a step-change. That's the honest read.

Informational and educational content only. Not investment advice.